Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Tribe Public Event “Addressing The Increasing Demand For Rare Cannabinoids”

Date: January 6, 2022

Time: 8:00am PT/ 11:00am ET

We are excited to be hosting Tribe Public’s Next Webinar Presentation and Q&A Event which will be held Thursday, January 6, 2022 (8 am PT/ 11 am ET). Our events are approximately 30 minutes in duration.

Eric A. Adams, CEO & President of InMed Pharmaceuticals, SVP, General Manager of BayMedica Shane Johnson, & VP, Commercial Operations Chris Meiering, PhD will co-host a presentation and Q&A event titled “Addressing The Increasing Demand For Rare Cannabinoids”. There will be a 5-10 minute Q&A session at the end of the presentation, so please send your questions for management to Tribe’s email: research@tribepublic.com.

Register for the event here.

Add to Calendar
« View all events
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*